We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Combined Gene and Radiation Therapy Induces Long-Term Prostate Cancer Remission

By LabMedica International staff writers
Posted on 22 Dec 2015
Print article
Image: The image on the left shows high-grade aggressive prostate cancer before treatment. The image on the right shows no evidence of cancer after combined gene therapy and radiotherapy (Photo courtesy of the Houston Methodist Hospital).
Image: The image on the left shows high-grade aggressive prostate cancer before treatment. The image on the right shows no evidence of cancer after combined gene therapy and radiotherapy (Photo courtesy of the Houston Methodist Hospital).
Results of a Phase II clinical trial indicated that an experimental gene therapy approach could successfully induce remission of prostate cancer when it was combined with directed radiation treatment.

Investigators at Houston Methodist Hospital (TX, USA) carried out the Phase II study on a group of 66 prostate cancer patients. The patient population was divided into two "arms": Arm A—low risk patients with cancer cells confined to the prostate, and Arm B—intermediate to high-risk patients with more aggressive prostate cancer.

The patients in Arm A were treated twice with intraprostatic injections of an adenoviral vector containing herpes simplex thymidine kinase (ADV/HSV-tk) followed by the antiviral drug valacyclovir. Patients in Arm B receive three injections of the adenoviral vector and valacyclovir. All patients were also treated with intensity-modulated radiotherapy (IMRT).

Results of the study, which followed the progress of the patients for a mean period of 100 months, were published in the December 12, 2015, online edition of the Journal of Radiation Oncology. They revealed that the 62 patients in both arms who completed the clinical trial had remarkably high five-year freedom from failure rates, meaning no indication by biochemical testing of cancer recurrence, of 94% and 91%, respectively. Prostate biopsies performed at 24 months after completion of treatment were negative in 83% of Arm A patients and 79% of Arm B patients. The majority of the patients in the clinical trial experienced few or no side effects or complications from the treatment regimen.

"We strategically used an adenovirus, similar to the one that causes the common cold, to carry the therapy agent—a herpes virus gene that produces the enzyme thymidine kinase or TK—directly into the tumor cells," said senior author Dr. E. Brian Butler, chairman of the department of radiation oncology at Houston Methodist Hospital. "Once the herpes virus gene was delivered and it started manufacturing TK, we gave patients a commonly used anti-herpes drug, valacyclovir. The combination attacked the herpes DNA, and the TK-producing tumor cells self-destructed, which is why the procedure is called "suicide gene therapy"."

Destruction of the tumor cells alerted the patients' immune systems to the presence of the cancer and triggered a massive immune response. "We have created a vaccine with the patient's own cancer cells, a treatment that complements, and may even enhance, what we can achieve with traditional radiation and hormonal therapies," said Dr. Butler.

A Phase III patient trial of the combination gene and radiation therapy, as required by the [US] Food and Drug Administration, is now underway.

Related Links:

Houston Methodist Hospital


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.